InSite Vision Completes Phase 3 Clinical Study of BromSite
The final patient has completed dosing and evaluation
in InSite Vision’s phase 3 clinical trial of BromSite (ISV-
303) for the reduction of pain and inflammation after
cataract surgery. BromSite combines a low dose (0.075%)
of the agent bromfenac with InSite Vision’s DuraSite
drug-delivery technology. Top-line data...